Finding new indications for drugs using the human interactome and network analysis
Indication expansion (drug repurposing / drug repositioning) is a compelling lifecycle management strategy which can provide extended patent protection and market exclusivity, while increasing franchise revenues mid-lifecycle. However, extending indications has been associated with high costs and high risks due to the requirement for additional clinical trials. Applying data-driven approaches to prioritizing indications can mitigate these risks and costs considerably. Network pharmacology is a systematic methodology using a human protein-protein interactome, which prioritizes disease protein networks and drug target networks, based on efficacy and safety insights. The data-driven approach combined with validation of prioritized indications in cell and animal models, reduces costs up to 70% and improves timelines by 10x.
Systematic Indication Prioritization
Novartis tasked BioXplor to prioritize novel indications for theirblockbuster drug, Cosentyx/Secukinumab, an IL17A inhibitor,. Applying our systematic indication prioritization system, the objective was to identify and prioritize novel indications for further clinical studies in inflammatory diseases, and to incorporate potential signals to explain adverse events from a phase 3 clnical trial which failed to meet expected end points. BioXplor analysed the pathogenic pathway of the disease and compared the treatment strategy with competing drug-target pathways. BioXplor's team utilized it's biomedical and drug disocvery knowledebase consisting of 250 databases and billions of unstructured biomedical literature sentences using natural language processing and machine learning models, to prioritize several novel indications based on safety and efficacy insights.
Case Study - Indication Prioritization for Cosentyx